Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry.
Ariëns LFM, van der Schaft J, Spekhorst LS, Bakker DS, Romeijn GLE, Kouwenhoven TA, Kamsteeg M, Voorberg AN, Oosting AJ, de Ridder I, Sloeserwij A, Haeck I, Thijs JL, Schuttelaar MLA, de Bruin-Weller MS.
Ariëns LFM, et al. Among authors: van der schaft j.
J Am Acad Dermatol. 2021 Apr;84(4):1000-1009. doi: 10.1016/j.jaad.2020.08.127. Epub 2020 Sep 16.
J Am Acad Dermatol. 2021.
PMID: 32946967